文献速递糖尿病

多组分整合照护对2型糖尿病替代临床结局的持续改善:系统综述与Meta分析

Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis.
PubMed 文献 · Diabetes Care · 2018-01-01

该研究基于181项随机对照试验(N=135,112),评估多组分整合照护对2型糖尿病替代临床结局的持续效果。Meta分析显示,HbA1c、收缩压、舒张压和LDL-C均显著改善,效应量较小;团队照护、患者教育/自我管理及医患沟通改善效应最大。

要点

  • 多组分整合照护可小幅但显著改善HbA1c、血压和LDL-C。
  • 亚组分析显示亚洲研究、年龄<60岁者HbA1c改善更明显。
  • 团队照护、患者教育/自我管理和医患沟通改善效应量最大。

核心结论

  • 多组分整合照护效应量较小(部分因背景照护良好而减弱),但团队照护和更好的信息流可能改善年轻、控制欠佳及低资源地区患者的医患沟通与自我管理。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed和Ovid MEDLINE(2000年1月至2016年8月),纳入181项随机对照试验(N=135,112),干预需包含两个及以上领域(卫生系统、卫生服务提供者或患者)的两项及以上质量改进策略,持续≥12个月,并报告至少一项临床结局。

主要发现

  • Meta分析(随机效应模型)显示,HbA1c汇总平均差为-0.28%(95%CI -0.35至-0.21)(-3.1 mmol/mol [-3.9至-2.3])。
  • 收缩压汇总平均差为-2.3 mmHg(95%CI -3.1至-1.4),舒张压为-1.1 mmHg(95%CI -1.5至-0.6),LDL-C为-0.14 mmol/L(95%CI -0.21至-0.07)。
  • LDL-C≥3.4 mmol/L患者效应更大:-0.31 vs. <3.4 mmol/L者-0.10 mmol/L(Pdifference=0.013)。
  • 亚洲研究HbA1c降幅大于北美:-0.51% vs. -0.23%(-5.5 vs. -2.5 mmol/mol;Pdifference=0.046)。
  • 持续>12个月研究效应更大:收缩压-3.4 vs. 12个月研究-1.4 mmHg(Pdifference=0.034);舒张压-1.7 vs. -0.7 mmHg(Pdifference=0.047);LDL-C -0.21 vs. -0.07 mmol/L(Pdifference=0.049);中位年龄<60岁患者HbA1c降幅大于≥60岁者:-0.35% vs. -0.18%(-3.8 vs. -2.0 mmol/mol;Pdifference=0.029)。

关键数值与推荐

  • 团队变更、患者教育/自我管理及改善医患沟通的效应量最大(0.28-0.36% [3.0-3.9 mmol/mol])。

临床怎么用

  • 在2型糖尿病管理中,可考虑实施包含团队照护、患者教育/自我管理和改善医患沟通的多组分整合照护策略。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The implementation of the Chronic Care Model (CCM) improves health care quality. We examined the sustained effectiveness of multicomponent integrated care in type 2 diabetes. RESEARCH DESIGN AND METHODS: We searched PubMed and Ovid MEDLINE (January 2000-August 2016) and identified randomized controlled trials comprising two or more quality improvement strategies from two or more domains (health system, health care providers, or patients) lasting ≥12 months with one or more clinical outcomes. Two reviewers extracted data and appraised the reporting quality. RESULTS: In a meta-analysis of 181 trials (N = 135,112), random-effects modeling revealed pooled mean differences in HbA1c of -0.28% (95% CI -0.35 to -0.21) (-3.1 mmol/mol [-3.9 to -2.3]), in systolic blood pressure (SBP) of -2.3 mmHg (-3.1 to -1.4), in diastolic blood pressure (DBP) of -1.1 mmHg (-1.5 to -0.6), and in LDL cholesterol (LDL-C) of -0.14 mmol/L (-0.21 to -0.07), with greater effects in patients with LDL-C ≥3.4 mmol/L (-0.31 vs. -0.10 mmol/L for <3.4 mmol/L; Pdifference = 0.013), studies from Asia (HbA1c -0.51% vs. -0.23% for North America [-5.5 vs. -2.5 mmol/mol]; Pdifference = 0.046), and studies lasting >12 months (SBP -3.4 vs. -1.4 mmHg, Pdifference = 0.034; DBP -1.7 vs. -0.7 mmHg, Pdifference = 0.047; LDL-C -0.21 vs. -0.07 mmol/L for 12-month studies, Pdifference = 0.049). Patients with median age <60 years had greater HbA1c reduction (-0.35% vs. -0.18% for ≥60 years [-3.8 vs. -2.0 mmol/mol]; Pdifference = 0.029). Team change, patient education/self-management, and improved patient-provider communication had the largest effect sizes (0.28-0.36% [3.0-3.9 mmol/mol]). CONCLUSIONS: Despite the small effect size of multicomponent integrated care (in part attenuated by good background care), team-based care with better information flow may improve patient-provider communication and self-management in patients who are young, with suboptimal control, and in low-resource settings.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lim LL, Lau ESH, Kong APS, et al. Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis. Diabetes Care. 2018. PMID: 29784698. doi:10.2337/dc17-2010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。